结外外周T细胞淋巴瘤：治疗挑战与未来展望
Nodal Peripheral T-Cell Lymphoma: Therapeutic Challenges and Future Perspectives.
作者信息
Lam Ho Pui Jeff, Amin Faisal, Arulogun Suzanne O, Gleeson Mary
机构信息
Department of Clinical Haematology, Guy's and St Thomas' NHS Foundation Trust, London SE1 9RT, UK.
出版信息
Cancers (Basel). 2025 Mar 28;17(7):1134. doi: 10.3390/cancers17071134.
Abstract
Peripheral T-cell lymphomas (PTCLs) present a significant clinical challenge despite recent advances in the development of novel therapeutic agents, guided by a deeper understanding of the pathobiology and the genetic and molecular characteristics underlying this complex and heterogeneous group of aggressive non-Hodgkin lymphomas (NHLs) [...].
摘要
外周T细胞淋巴瘤（PTCLs）是一种具有显著临床挑战的疾病，尽管在新型治疗药物的研发方面取得了进展，这些进展是在对这种复杂且异质性的侵袭性非霍奇金淋巴瘤（NHLs）的病理生物学以及遗传和分子特征有更深入理解的指导下取得的[...]。
相似文献
1
Nodal Peripheral T-Cell Lymphoma: Therapeutic Challenges and Future Perspectives.结外外周T细胞淋巴瘤：治疗挑战与未来展望
Cancers (Basel). 2025 Mar 28;17(7):1134. doi: 10.3390/cancers17071134.
2
BV and beyond: how to incorporate novel agents into PTCL management.外周T细胞淋巴瘤（PTCL）的治疗进展：如何将新型药物纳入PTCL的治疗方案。
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):54-61. doi: 10.1182/hematology.2024000530.
3
Frontline Management of Nodal Peripheral T-Cell Lymphomas.结外边缘区 T 细胞淋巴瘤的一线治疗。
Am Soc Clin Oncol Educ Book. 2023 May;43:e390334. doi: 10.1200/EDBK_390334.
4
[Current treatment strategies for peripheral T-cell lymphoma].[外周T细胞淋巴瘤的当前治疗策略]
Rinsho Ketsueki. 2021;62(8):1112-1120. doi: 10.11406/rinketsu.62.1112.
5
Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.间变性大细胞淋巴瘤（ALCL）和其他 CD30+外周 T 细胞淋巴瘤的治疗：重点介绍 Brentuximab vedotin。
Semin Hematol. 2021 Apr;58(2):85-94. doi: 10.1053/j.seminhematol.2021.02.006. Epub 2021 Mar 6.
6
First-Line Therapy for Nodal T-cell Non-Hodgkin Lymphomas: an Unmet Need in Hematology.结外 T 细胞非霍奇金淋巴瘤的一线治疗：血液学中的未满足需求。
Curr Oncol Rep. 2023 Jul;25(7):813-824. doi: 10.1007/s11912-023-01400-w. Epub 2023 Apr 12.
7
Pathological and Molecular Features of Nodal Peripheral T-Cell Lymphomas.淋巴结外周T细胞淋巴瘤的病理和分子特征
Diagnostics (Basel). 2022 Aug 18;12(8):2001. doi: 10.3390/diagnostics12082001.
8
Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.抗 CD30 抗体药物偶联物治疗淋巴瘤：现有知识、尚存争议和未来展望。
Ann Hematol. 2023 Jan;102(1):13-29. doi: 10.1007/s00277-022-05054-9. Epub 2022 Dec 13.
9
Current Concepts in Nodal Peripheral T-Cell Lymphomas.当前关于结外外周 T 细胞淋巴瘤的概念。
Surg Pathol Clin. 2023 Jun;16(2):267-285. doi: 10.1016/j.path.2023.01.011. Epub 2023 Apr 3.
10
Current management of peripheral T-cell lymphomas.外周T细胞淋巴瘤的当前管理
Cancer Treat Res. 2015;165:289-303. doi: 10.1007/978-3-319-13150-4_12.
引用本文的文献
1
B-Cell Lymphomas Secrete Novel Inhibitory Molecules That Disrupt HLA Class II-Mediated CD4+ T-Cell Recognition.B细胞淋巴瘤分泌新型抑制分子，破坏HLA II类介导的CD4+ T细胞识别。
Cells. 2025 Aug 7;14(15):1220. doi: 10.3390/cells14151220.
本文引用的文献
1
A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma.林匹利昔单抗治疗复发和/或难治性外周 T 细胞淋巴瘤患者的 Ib 期研究。
Clin Cancer Res. 2024 Oct 15;30(20):4593-4600. doi: 10.1158/1078-0432.CCR-24-1194.
2
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study.本妥昔单抗维迪辛联合环磷酰胺、多柔比星、依托泊苷和泼尼松治疗 CD30 阳性外周 T 细胞淋巴瘤：一项多中心、单臂、2 期研究。
Lancet Haematol. 2024 Sep;11(9):e671-e681. doi: 10.1016/S2352-3026(24)00171-6. Epub 2024 Jul 24.
3
Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma.复发/难治性外周 T 细胞淋巴瘤的新型临床风险分层和治疗策略。
J Hematol Oncol. 2024 Jun 1;17(1):38. doi: 10.1186/s13045-024-01560-7.
4
Lorlatinib Versus Crizotinib in Patients With Advanced -Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.洛拉替尼对比克唑替尼用于治疗晚期 ALK 阳性非小细胞肺癌患者：III 期 CROWN 研究的 5 年结果。
J Clin Oncol. 2024 Oct 10;42(29):3400-3409. doi: 10.1200/JCO.24.00581. Epub 2024 May 31.
5
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.口服阿扎胞苷与滤泡辅助 T 细胞淋巴瘤（ORACLE）患者标准治疗的比较：一项开放标签随机 3 期研究。
Lancet Haematol. 2024 Jun;11(6):e406-e414. doi: 10.1016/S2352-3026(24)00102-9.
6
A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas.一种实用的方法，用于现代 T 细胞和 NK 细胞淋巴瘤的诊断和分类。
Blood. 2024 Oct 31;144(18):1855-1872. doi: 10.1182/blood.2023021786.
7
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.戈利替尼，一种选择性JAK1酪氨酸激酶抑制剂，用于治疗难治性或复发性外周T细胞淋巴瘤患者（JACKPOT8研究B部分）：一项单臂、多中心、2期研究。
Lancet Oncol. 2024 Jan;25(1):117-125. doi: 10.1016/S1470-2045(23)00589-2. Epub 2023 Dec 9.
8
Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions.结外周 T 细胞淋巴瘤的病理生物学：当前认识与未来方向。
Haematologica. 2023 Dec 1;108(12):3227-3243. doi: 10.3324/haematol.2023.282716.
9
Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial.普拉曲沙注射联合 CHOP 方案治疗外周 T 细胞淋巴瘤：Fol-CHOP 剂量探索 1 期临床试验结果。
Blood Adv. 2024 Jan 23;8(2):353-364. doi: 10.1182/bloodadvances.2023011095.
10
Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma.罗米地辛联合来那度胺治疗未经治疗的外周 T 细胞淋巴瘤的多中心 2 期研究。
Blood Adv. 2023 Oct 10;7(19):5771-5779. doi: 10.1182/bloodadvances.2023009767.
Zotero 插件